Nutex Health director sells 203 shares at $214

A Nutex Health director reported a modest open-market or private sale and now directly holds 400 common shares.

Rhea-AI Filing Summary

Nutex Health Inc. (NUTX) director Scott J. Saunders reported selling 203 shares of common stock on September 18, 2026 in a sale described as an open market or private transaction at $214.25 per share. Following this transaction, he directly holds 400 Nutex Health common shares, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Net Seller: 203 shares

Net Sell 1 txn

Insider Saunders Scott J

Role Director

Sold 203 shs ($43K)

Type	Security	Shares	Price	Value
Sale	Common Stock	203	$214.25	$43K

Holdings After Transaction: Common Stock — 400 shares (Direct)

Key Figures

Shares sold: 203 shares Sale price per share: $214.25 per share Shares held after transaction: 400 shares +1 more

4 metrics

Shares sold 203 shares Common stock sale by director on September 18, 2026

Sale price per share $214.25 per share Price for the 203 Nutex Health common shares sold

Shares held after transaction 400 shares Director’s direct Nutex Health common stock holdings after the sale

Net shares sold 203 shares Net sell direction across all reported transactions in this Form 4

Key Terms

Rule 10b5-1, open market or private transaction, beneficial ownership

3 terms

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open market or private transaction market

"Sale in open market or private transaction of Nutex Health common stock"

beneficial ownership financial

"Form 4 reports changes in beneficial ownership by the director"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nutex Health (NUTX) disclose in this Form 4?

Nutex Health disclosed that director Scott J. Saunders sold 203 shares of its common stock on September 18, 2026 in a sale described as an open market or private transaction.

At what price were the Nutex Health (NUTX) shares sold by the director?

The 203 Nutex Health shares reported by director Scott J. Saunders were sold at a price of $214.25 per share in a transaction described as an open market or private transaction.

How many Nutex Health (NUTX) shares does the director hold after this sale?

After the sale on September 18, 2026, director Scott J. Saunders directly holds 400 shares of Nutex Health common stock, as reported in the Form 4 filing.

Was the Nutex Health (NUTX) insider sale made under a Rule 10b5-1 plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not affirmed, so the reported September 18, 2026 sale was not identified as made under a Rule 10b5-1 trading plan.

What is the net share change from the reported Nutex Health (NUTX) insider transaction?

The Form 4 shows a net disposition of 203 shares of Nutex Health common stock by director Scott J. Saunders, resulting from a single reported sale transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 02:52 PM Accepted by SEC EDGAR 09/18/2026 - 02:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saunders Scott J

(Last) (First) (Middle)

1776 YORKTOWN STREET SUITE 700

C/O NUTEX HEALTH INC.

(Street)

HOUSTON TEXAS 77056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/18/2026		S		203	D	$214.25	400	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Scott J. Saunders	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)